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Abstract 
Half of all patients diagnosed with pancreatic ductal adenocarcinoma (PDAC) die within 
a year despite extensive surgery and/or a highly aggressive chemotherapy regimen. Several 
mechanisms are proposed to play a role in PDAC therapeutic resistance, including reactive 
stroma and hypoxia. Hypoxia signaling creates a more aggressive phenotype with increased 
metastatic potential and impaired therapeutic efficacy. Carbonic anhydrase IX (CA9) functions 
as part of the cellular hypoxia response to regulate intracellular pH, promoting cell survival. 
Apurinic/Apyrimidinic Endonuclease-1-Reduction/oxidation Effector Factor 1 (APE1/Ref-1) is a 
multi-functional protein with two major activities: an endonuclease function in DNA base 
excision repair and a redox signaling function that reduces oxidized transcription factors, 
enabling them to bind to their DNA target sequences. APE1/Ref-1 regulates several transcription 
factors involved in survival mechanisms, tumor growth, and hypoxia signaling. We explored the 
mechanisms underlying PDAC cell responses to hypoxia and modulation of APE1/Ref-1 redox 
signaling control of hypoxia inducible factor 1 alpha (HIF1α), a critical factor in hypoxia-
induced CA9 transcription. We hypothesized that obstructing the HIF-CA9 axis at two 
points via APE1/Ref-1 inhibition and CA9 inhibition will result in enhanced PDAC cell 
killing under hypoxic conditions. 
 Methods: We performed qRT-PCR and Western Blots to confirm changes in CA9 
expression in PDAC cells following APE1/Ref-1 inhibition and hypoxia exposure. Proliferation 
assays were used to assess cell killing following inhibition of APE1/Ref-1 and CA9 under 
hypoxia. Ex vivo 3-Dimensional co-culture models including both tumor and CAFs were used to 
examine whether we could enhance the efficacy of APE1/Ref-1 and/or CA9 inhibition with a 
dual-targeting approach to kill tumor spheroids. 
Results: HIF1α-mediated induction of CA9 is significantly diminished in PDAC cells 
following APE1/Ref-1 redox inhibition. Additionally, dual-targeting of APE1/Ref-1 and CA9 
reduces PDAC tumor cell growth under hypoxic conditions and in 3D tumor co-cultures. 
